Clinical outcomes of laparoscopic-assisted synchronous bowel anastomoses for synchronous colorectal cancer: initial clinical experience
PDF | HTML | How to cite
Metrics: PDF 1373 views | HTML 1866 views | ?
Zhengtian Li1,*, Dawei Wang1,*, Yunwei Wei1, Peng Liu2 and Jun Xu1
1 Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
2 Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China
* These authors have contributed equally to this work
Jun Xu, email:
Keywords: colorectal surgery; laparoscopy; synchronous bowel anastomoses; synchronous colorectal cancer
Received: September 24, 2016 Accepted: October 17, 2016 Published: November 03, 2016
The primary aim of this study was to explore the safety and feasibility of laparoscopic-assisted synchronous bowel anastomoses (LSBA) for synchronous colorectal cancer (SCRC). All patients who underwent LSBA for SCRC were retrospectively reviewed and analyzed for clinical and pathological features, technical feasibility and short-term as well as long-term oncological outcomes. Between July 2008 and January 2012, a series of 11 consecutive SCRC patients underwent LSBA. Six patients underwent laparoscopic-assisted right hemicolectomy and anterior resection. Five patients had laparoscopic-assisted right hemicolectomy and sigmoidectomy. There were no intraoperative complications that required open conversions. Mean operation time was 233 (range, 195–285) minutes, and mean estimated blood loss was 224 (range, 100–300) mL. The postoperative course of the patients was uneventful with the mean return to oral intake was 6.9 (range 5–12) days, and mean length of hospital stay was 12.6 (range 9–17) days. All surgical wounds showed good cosmetic outcome, and the mean incision length was 4.1 (range 3.5-5.0) cm. During a median follow-up period of 76 months, no local tumor recurrences were found. LSBA is a potentially feasible and safe procedure for SCRC when performed by an experienced surgeon. Further large clinical controlled trials are warranted to confirm the findings.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.